Where most tele-health platforms base their diagnoses on declarative data, SheMed relies on biological analyzes to adapt treatments to each patient. A way to restore its place to clinical data in a sector long dominated by standardized approaches.
The heart of the model is based on the use of biomarkers and complete blood tests to determine eligibility for treatments based on GLP-1, a class of drugs popularized by Wegovy (Novo Nordisk) and Mounjaro (Eli Lilly). These treatments, originally designed for diabetes management, are now used for metabolic management and weight loss. By integrating biological results into the prescription, SheMed seeks to avoid the simplifying logic of BMI, often criticized for its lack of reliability in the assessment of women’s health.
The course offered by SheMed combines medical monitoring supervised by practitioners, digital continuous measurement tools and psychological support. The objective is to link the physiological and behavioral dimensions of female metabolic health, while respecting the hormonal variability specific to each patient.
The company plans to release results this month from the first European clinical trial dedicated to the impact of GLP-1 drugs on women’s hormonal and metabolic health. This work, carried out with thousands of users, should make it possible to identify differentiated responses according to biological profiles. It could help to redefine protocols for managing female metabolism, long based on male models.
Founded in April 2024 in London by Olivia Ferro and her sister Chloe Ferro, SheMed has raised 43 million euros ($50 million) in series A to expand its operations in the United Kingdom, strengthen its medical teams and support its research programs. The platform claims more than 60,000 members and aims to improve access to preventive medicine, based on data and focused on the real needs of women.
